The recent completion of BayWa’s sale of Cefetra has provided a fresh capital injection, yet it also underscores the significant scale of the remaining financial overhaul required. While the deal marks a step forward, the journey toward a stabilized balance sheet is protracted, with critical milestones still ahead.
Capital Inflows and the Long Road Ahead
Proceeds from the Cefetra divestment are strengthening BayWa’s liquidity. An initial €80 million was received at closing, with a further €45 million due by April 30, 2026. This final tranche is subject to a potential reduction of up to €5 million for early payment. Additionally, approximately €62 million is expected from the repayment of shareholder loans tied to Cefetra’s refinancing.
The true impact, however, lies beyond the direct purchase price. By deconsolidating the Dutch subsidiary and applying the proceeds to debt repayment, the group’s bank liabilities are reduced by over €600 million. Combined with other divestments planned for 2025, total debt reduction is projected to reach €1.3 billion.
This figure, while substantial, represents only the initial phase. The company’s restructuring blueprint mandates a total debt reduction of €4 billion by 2028, meaning the current progress covers just under one-third of the necessary path.
Strategic Divestments: The Complex Case of T&G Global
Attention now turns to the next major asset on the sale block: T&G Global. BayWa holds a 73.9% stake in this New Zealand-based fruit marketing business, known for global apple brands such as Envy and Jazz. T&G reported revenue of $1.3 billion in 2024 and returned to profitability with a net income of $16 million, a notable recovery from a $9.9 million loss the previous year. The sales process is being advised by Goldman Sachs.
Should investors sell immediately? Or is it worth buying BayWa?
The transaction faces complications, however. Minority shareholders, including the Hong Kong-based Joy Wing Mau Group which holds nearly 20%, could pose challenges. The anticipated proceeds from this sale are estimated at around €300 million.
Creditor Negotiations Set the Pace
The entire restructuring timetable hinges on negotiations with creditor banks. Securing an extension of the current standstill agreement until autumn 2026 is crucial for management to gain the necessary operational breathing room. The audited group financial statements for 2025 will be delayed until the fourth quarter of 2026 due to the complex restructuring, leaving investors with limited data transparency until then.
Management has already adjusted its financial guidance. The outlook for 2026 has been withdrawn, and the adjusted EBITDA target for 2027 has been lowered to approximately €140 million. The strategic plan through 2028 involves focusing on four core business areas, reducing the workforce by roughly 1,300 positions, and scaling back group revenue to about €10 billion.
This comprehensive transformation is not a quick fix but a multi-year marathon. Its ultimate success will be determined by the outcome of decisive bank negotiations in the coming months.
Ad
BayWa Stock: Buy or Sell?! New BayWa Analysis from April 4 delivers the answer:
The latest BayWa figures speak for themselves: Urgent action needed for BayWa investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 4.
BayWa: Buy or sell? Read more here...









